Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $1.55M, compared with -$1.57M a year earlier. Trailing-twelve-month net income was -$1.48M. Over 3 fiscal years it compounded at -20.1% a year.
Context
- Net income amounted to 5.8% of revenue in FY2025, down 4.0 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $58.1M (+1362.8%) for the fiscal year ending Dec 2026, a step up from the +20.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.55M+4.8% QoQ
- Last fiscal yearDec 2025
- -$4.6M+20.4% YoY
- LTMMar 2026
- -$1.48M-67.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +198.9% | +344.2% | +145.4 pp |
| 1 year | +20.4% | +1362.8% | +1342.4 pp |
| 3-year CAGR | -20.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (4.6M) USD
- Year-over-year change
- -20.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.6M) | -20.4% |
| FY2024 | 2024-12-31 | (3.82M) | -308.4% |
| FY2023 | 2023-12-31 | (936K) | +89.6% |
| FY2022 | 2022-12-31 | (9.02M) | -361.4% |
| FY2021 | 2021-12-31 | (1.96M) | — |
Net Income vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 net income of $1.48M is the smallest of the 10 companies compared; the peer median is $35.1M.
- Its year-over-year change of -67.8% is the 9th highest of 10, against a peer median of +65.1%.
- Net income amounts to 1.7% of revenue for ETON, versus a peer median of 37.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $546.15M | +113.1% | +12.2% | 56.9% | |
| LTM Mar 2026 | $166.01M | +74.3% | +67.3% | — | |
| LTM Sep 2026 | $146.22M | +65.1% | -57.4% | 22.5% | |
| LTM Mar 2026 | $122.65M | +233.3% | — | 100.3% | |
| LTM Mar 2026 | $35.1M | +30.0% | +33.8% | — | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| LTM Mar 2026 | $14.61M | +298.9% | -42.4% | 4.0% | |
| LTM Mar 2026 | $8.38M | -42.0% | -24.3% | 16.4% | |
| LTM Mar 2026 | $1.48M | -67.8% | -20.1% | 1.7% | |
| Peer median (excluding ETON) | $35.1M | +65.1% | -13.8% | 37.5% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.